PTC/SB/05 (06-03)
Approved for use through 07/31/2003. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number

	arwork Reduction Act of 1995, no perso	ons are required to re	espond to a collection of into	I DC25479A			
Under the Paperwork Reduction Act of 1995, no persons are required to UTILITY PATENT APPLICATION TRANSMITTAL			Attorney Docket No.	PC25475A			
		N T	First Inventor	TERO AHOLA			
		"	Title	PARMACEUTICAL			
		t	Express Mail Label No.	EL 969716656 L	JS		
	ations under 37C.F.R. §1.53(b)) APPLICATION ELEMENTS 500 concerning utility patent application		ADDRESS TO:	Commissioner	Mail Stop Patent <u>Applications</u> Commissioner for Patents Box 1450 Alexandria, VA 22313-1450		
Fee 1 (Submit a Applii See 3 Spec (prefe - D - C - S - R 0 - B - E	Fransmittal Form (e.g., PTO/SB/17 or original, and a duplicate for fee procession cant claims small entity status 37 CFR 1.27 diffication [Total Pages arred arrangement set forth below) escriptive title of the Invention ross References to Related Applicatement Regarding Fed sponsore deference to sequence listing, a talk of a computer program listing appearance of Summary of the Invention strief Description of the Drawings (in Detailed Description of the Drawings (in Detailed Description of the Drawings (in Description of Desc	19] sations ad R&D ole, andix	computer F 8. Nucleotide and/o (if applicable, all a. Co b. Specifica i. Co ii. P c. SS ACCOMP 9. Assignme 10. 37 CFR 3. (when the	mputer Readable Contion Sequence Listin D-ROM or CD-R (2 contemporary aper attement verifying identifying ANYING APPLICATION of Papers (cover short papers)	opy (CRF) g on: copies) entity of above copies ATION PARTS eet & document(s)) Power of Attorney		
4. Drav 5. Oatl a. b.	wing(s) (35 U.S.C. 113) [Total sheet of the Disclosure wing(s) (35 U.S.C. 113) [Total sheet of the property of	pes] copy) CFR §1.63(d)) ox 18 completed) VENTOR(S) eting inventor(s) see 37 CFR	12. Informati Statemer 13. Prelimina 14. Return F (Should 15. Certified (if foreig 16. Nonpub (b)(2)(B or its ed	luivalent. Copy of Priority Assig	Copies of IDS Citations PEP 503) zed) cument(s) ler 35 U.S.C. 122 attach form PTO/SB/35 nment Papers		
18. If a COl	NTINUING APPLICATION, check of Application Data Sheet under 37CFR 1	appropriate box, and .76.	I supply the requisite inform				
Prior a	ontinuation Divisional opplication information: Examon OR DIVISIONAL APPS only; The exid a part of the disclosure of the accomen can only be relied upon when a port	miner mire disclosure of the panying combinuation	tion-in-part (CIP) the prior application, from who or divisional application a ritently omitted from the subsection of	ESS	Unit: ion is supplied under Box ed by reference.		
Custome	r Number 28940			or	ondence address below		
1	Pfizer Inc.						
Nome	Lazzz Calanca Center Drive						
Name Address				Zin Code	92121		
Name Address City	10777 Science Center Drive San Diego	State Telephone	CA 858-526-4608	Zip Code Fax	92121 858-678-8233		

Signature

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for replace application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for replace the formation formation of time you require to complete this form and/or suggestions for replace the formation formation of time you require to complete this form and/or suggestions for required to complete the formation of time you require to complete this form and/or suggestions for required to complete the formation of time you require to complete this form and/or suggestions for required to complete the formation of time you require to complete the formation of time you require to complete this form and/or suggestions for required to complete the formation of time you require to complete this form and/or suggestions for time you require to complete this formation of time you require to complete the formation of time you require to com

17638

PTO/SB/17 (05-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office;U.S. DEPARTMENT OFCOMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2003						Complet if Kn wn									
						Application Number TB					A				
						Filing Date HE				EREWITH					
											RO AHOLA				
Effective 01/01/2003. Patent fees are subject to annual revision.						Examiner Name TB									
Applicant claims small status. See 37 CFR 1.27					Art Unit TE										
Total Amount of Payment (\$)1,488.00 METHOD OF PAYMENT (check all that apply)						Attorney Docket No. PC25479A FEE CALCULATION (continued)									
Check Credit Card Money Other None						3. ADDITIONAL FEES									
Order						Large Entity Small Entity									
Deposit Account:						Fee Code	Fee (\$)	Fee Code	Fee (\$)		Fee Description				
Deposit 500329					1051	130	2051	65	Surcharge	– late fee or oath		Paid			
Account															
Deposit Agouron Pharmaceuticals, Inc.						1052	50	2052	25	Surcharge	late filing fee or co	ver sheet			
Account										•	-				
Name The Di	L rector is	authorize	d to: (check all that apply	i v)	1053	130	1053	130	Non-English	lon-English specification				
_				Credit any over	• •	1812	2,520	1812	2,520	For filing a request for reexamination			 		
☐ Charge fee(s) indicated below ☐ Credit any overpayments ☐ Charge any additional fee(s) during the pendency of this application						1804	920*	1804	920*	Requesting publication of SIR prior to					
_						i				Examiner a	Examiner action				
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.						1805	1,840*	1805	1,840*		equesting publication of SIR after caminer action				
_	ALCULA					1251	110	2251	55	Extension for reply within first month					
1. BAS	IC FILING	G FEE				1252	410	2252	205	Extension for reply within second month					
Large I						1253	930	2253	465	Extension for reply within third month					
Fee	Fee	Fee	Fee	Fee Description	Fee Paid	1254	1,450	2254	725	Extension f	or reply within fourt	h month			
Code	(\$)		(\$)					l .							
1001	770		375	Utility filing fee	770	1255	1,970	2255	985	Extension f	or reply within fifth r	month			
1002	330	2002	165	Design filing fee		1401	320	2401	160	Notice of A	ppeal				
1003	520	l	260	Plant filing fee		1402	320	2402	160	Filing a brie	f in support of an a	ppeal			
1004	750	1	375	Reissue filing fee		1403	280	2403	140	Request for	r oral hearing				
1005	160	2005	80	filing fee		1451	1,510	1451	1,510	Petition to i proceeding	nstitute a public use	•			
		1				1452	110	2452	55		evive unavoidable				
			Subto	otal (1) \$	770	1453	1,300	2453	650	Petition to r	evive – unintention	al	\exists		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE							1,300	2501	650	Litility issue	fee (or reissue)				
Extra Claims Fee from Fee Paid						1501 1502	470	2502	235	Design issue fee			=		
Total CI	oime		20 -	below							_				
		30	- 20 =	16 X 18.00	= 288.00	1503	630	2503	315	Plant issue	fee				
Independ Claims	uent	8	- 3 =	5 × 86.00	= 430.00	1460	130	1460	130	Petitions to	the Commissioner				
Multiple Dependent 0 = 0						1807	50	1807	50	Petitions to	Petitions to the Commissioner				
Large I	Entity	Small Er	ntity			1806	180	1806	180	Submission	of Information Disc	closure Stmt			
Fee Code	Fee (\$)		Fee (\$)	Fee Description		8021	40	8021	40	₹.	each patent assignment				
1202	(\$) 18	2202	(\$) 9	Claims in excess of 20		1809	750	2809	375	Filing a sub	nes number of prop mission after final r				
1201	86	2201	42	Independent claims in	excess of 3	1810	750	2810	375	For each ac	37 CFR 1.129(a)) or each additional invention to be				
1203	290	2203	140	Multiple dependent cla	im. if not paid	1801	750	2810	375		37 CFR 1.129(b)) Continued Examin	ation (RCF)			
1204	84	2204	42	**Reissue independent		1802	900	1802	900	•	quest for Continued Examination (RCE)				
				original pat	ent					of a design	application		L		
1205	18	2205	9	**Reissue independent original pat		1802	900	1802	900	Request for of a design	expedited examina application	ition			
		-		,		Other F	ee (specif	()		J	÷ •				
SUBTOTAL (2) (\$) 718.00 *Reduced by Basic F								c Filing I			ubtotal (3)_	(\$)			
SUBMITTED BY (Complete if applicable)															
Name (Printed/Type) Keith D. Hutchinson						tration N ney Agei		687		Telephone	858-526-460	ช ∙			
Signature Red () Ol-tolerida							Agei	/_1			Date	11.4.1	2002		

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 137 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and for suggestions for reduient this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pto-9199 and select option2.

PC25479 Non-Provisional Application certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail EL 969716656 US in an envelope addressed to: Mail Stop: Patent Applications, Commissioner for Patents,

PO Box 1450, Alexandria, VA 22313-1450 on this 17th day of October 2003.

Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: TERO AHOLA, ET. AL.

Group Art Unit: Not Yet Assigned

Serial No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: Herewith

For: PHARMACEUTICAL

Mail Stop: Patent Applications

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

Transmittal Letter 1. 1 page; 2. **Application Data Sheet** 3 pages; 3. **Utility Patent Application Transmittal** 1 page; 4. Fee transmittal 1 page; 5. Specification 19 pages; Claims (4 pages) Abstract (1 page) 6. Drawings (9 pages) 9 pages; Copy of Priority Assignment 7. 11 pages;

8. Return Postcard 1 page; and 9. Total Fee Due \$1,488.00 Deposit Account

Respectfully submitted,

Date: Det . 16, 2003

Keith D. Hutchinson Attorney For Applicants Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company

Patent Department 10777 Science Cent

10777 Science Center Drive San Diego, California 92121 Phone: (858) 526-4608

Fax: (858) 678-8233